4 completed, 1 terminated, 1 withdrawn. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow Abituzumab: new trials by email Literature Review of Abituzumab trials Research Report on Abituzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. abituzumab, Placebo + Cetuximab + FOLFIRI - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | SFJ Pharmaceuticals X, LTD. | 2019-04-01 | 2020-03-18 | |
| Abituzumab in SSc-ILD Abituzumab 1500 mg, Abituzumab 500 mg, Placebo - Systemic Sclerosis-associated Interstitial Lung Disease | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 24 | 2016-05-31 | 2019-06-18 |
| EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer EMD 525797, Placebo, Standard of Care (SoC) - Prostate Cancer Metastatic | Phase 2 | Completed | EMD Serono | 180 | 2011-04-01 | 2015-12-14 |
| EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer EMD 525797 250 mg, EMD 525797 500 mg, EMD 525797 750 mg - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 232 | 2009-10-01 | 2016-03-30 |
| EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases EMD 525797 - Colorectal and Ovarian Cancer Patients With Liver Metastases | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 41 | 2009-02-01 | 2015-12-14 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer EMD 525797 - Prostate Cancer, Bone Metastases | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 26 | 2008-10-01 | 2017-08-02 |
Colorectal Neoplasms (2) · Lung Diseases, Interstitial (1) · Prostatic Neoplasms (1) · Scleroderma, Systemic (1)
Merck KGaA, Darmstadt, Germany (3) · EMD Serono (1) · EMD Serono Research & Development Institute, Inc. (1) · SFJ Pharmaceuticals X, LTD. (1)
Belgium (3) · Germany (3) · Poland (3) · Spain (3) · United Kingdom (3) · Australia (2) · Canada (2) · Israel (2) · Russia (2) · United States (2) · Argentina (1) · Bulgaria (1) · Cyprus (1) · Czechia (1) · France (1)
Dirk Arnold, Prof. Dr. (1) · Prof. Josep Tabernero (1) · Wolfgang Uhl, Dr, Dipl. Chem., Physician (1)
PMID 23791392, PMID 25319061, PMID 33004536
2008 (1), 2015 (1), 2018 (1)